Matsuoka Hideki, Hamada Rikuzo
Division of Neurology, National Hospital Kyushu Cardiovascular Center, 8-1 Shiroyama-cho, Kagoshima City 892-0853, Japan.
CNS Drugs. 2002;16(8):509-16. doi: 10.2165/00023210-200216080-00001.
Intracerebral haemorrhage (ICH) results in high mortality and morbidity. The most important causes of neurological deterioration after ICH are progression of oedema and injury to nerve cells and axons surrounding the haematoma, as well as haematoma enlargement. Recent studies have indicated that thrombin, formed upon clotting of the haematoma, plays an important role in these processes. As opposed to conventional therapeutic approaches, administration of a thrombin inhibitor could effectively limit oedema formation and neuronal damage, improving survival and functional outcome. A small, preliminary clinical trial has suggested that antithrombin therapy with intravenously administered argatroban may be useful in treatment of ICH. Randomised, controlled studies are needed to confirm these initial findings.
脑出血（ICH）会导致高死亡率和高发病率。脑出血后神经功能恶化的最重要原因是水肿进展、血肿周围神经细胞和轴突损伤以及血肿扩大。最近的研究表明，血肿凝结时形成的凝血酶在这些过程中起重要作用。与传统治疗方法不同，给予凝血酶抑制剂可有效限制水肿形成和神经元损伤，提高生存率和功能结局。一项小型初步临床试验表明，静脉注射阿加曲班进行抗凝血酶治疗可能对脑出血治疗有用。需要进行随机对照研究来证实这些初步发现。
